Sugi Predict

Sugi Predict / Compounds / SCHEMBL980158

SCHEMBL980158

SCHEMBL980158

COc1ccc(-c2cccc(N)c2)cn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B1 P14061 1/20 0.65
▸ HSD17B2 P37059 1/20 0.65
▸ MAP4K4 O95819 4/20 0.62
▸ KDR P35968 1/20 0.59
▸ EPHB4 P54760 1/20 0.59
▸ TEK Q02763 1/20 0.59
▸ ADORA2A P29274 1/20 0.56
▸ ADORA1 P30542 1/20 0.56
▸ PIK3CA P42336 2/20 0.54
▸ PIK3CD O00329 1/20 0.54
▸ PIP5K1C O60331 1/20 0.54
▸ PIK3CB P42338 1/20 0.54
▸ PI4KA P42356 1/20 0.54
▸ PIK3CG P48736 1/20 0.54
▸ PI4KB Q9UBF8 1/20 0.54
▸ MKNK1 Q9BUB5 2/20 0.50
▸ MKNK2 Q9HBH9 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ PSIP1 O75475 1/20 0.50
▸ AXL P30530 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13575386 0.81 HSD17B1 (0.67) HSD17B1HSD17B2MAP4K4KDRADORA2A
SCHEMBL13575381 0.81 HSD17B1 (0.67) HSD17B1HSD17B2KDRADORA2AADORA1
SCHEMBL12498936 0.81 HSD17B1 (0.67) HSD17B1HSD17B2KDRADORA2AADORA1
SCHEMBL30578438 0.80 MKNK1 (0.62) HSD17B1HSD17B2KDREPHB4TEK
SCHEMBL3077045 0.80 MKNK1 (0.62) HSD17B1HSD17B2KDREPHB4TEK
SCHEMBL17547019 0.80 HSD17B1 (0.65) HSD17B1HSD17B2KDREPHB4TEK
SCHEMBL5673332 0.80 HSD17B1 (0.97) HSD17B1HSD17B2KDRADORA2AADORA1
SCHEMBL13575397 0.80 HSD17B1 (0.65) HSD17B1HSD17B2KDREPHB4TEK
SCHEMBL31174412 0.80 CYP2A6 (0.68) HSD17B1HSD17B2PIK3CAPIK3CDPIP5K1C
SCHEMBL3754419 0.80 CYP2A6 (0.68) HSD17B1HSD17B2PIK3CAPIK3CDPIP5K1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024262911-A1 NOVEL PYRAZOLO PYRIMIDINE-BASED COMPOUND AND USE THEREOF 주식회사 에이조스바이오 2024-12-26 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 — — EP disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 — — EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-8642788-B2 Activators of executioner procaspases 3, 6 and 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-02-04 — — US disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20110021522-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-01-27 — — US disclosed
EP-2237784-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 The Regents of the University of California (US) 2010-10-13 — — EP disclosed
WO-2009089508-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK HSD17B1 3462/4885HSD17B2 3248/4885MAP4K4 186/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK HSD17B1 4031/4885HSD17B2 3906/4885MAP4K4 191/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK HSD17B1 3462/4885HSD17B2 3248/4885MAP4K4 186/4885
US-20110021522-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 CASP7, CASP3, CASP6 HSD17B1 4161/4885HSD17B2 4484/4885MAP4K4 2317/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK HSD17B1 3462/4885HSD17B2 3248/4885MAP4K4 186/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 HSD17B1 4613/4885HSD17B2 4636/4885MAP4K4 263/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK HSD17B1 3561/4885HSD17B2 3401/4885MAP4K4 169/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK HSD17B1 3561/4885HSD17B2 3401/4885MAP4K4 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.